Brief: Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study
23/10/2023 12:12
Oct 23 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS PRESENTS POSITIVE UPDATED PANCREATIC CANCER
DATA FROM
GOBLET PHASE 1/2 STUDY AT ESMO
Source text for Eikon: ID:nPn1vZw6Ja
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer